Filing Overview
MiNK Therapeutics, Inc. filed a Form 8-K dated March 2, 2022, reported on March 8, 2022, under Item 5.02 regarding executive employment agreements and compensation arrangements. The company is incorporated in Delaware and its common stock trades on Nasdaq under the symbol INKT.
Executive Compensation and Key Changes
- President and Chief Executive Officer Dr. Jennifer Buell entered into an employment agreement effective March 3, 2022. Her annual base salary is $425,000, with a discretionary bonus target of 50% of base salary. Compensation and benefits are retroactive to January 1, 2022.
- Chief Scientific Officer Dr. Marc van Dijk, formerly Chief Technology Officer, entered into an employment agreement effective March 2, 2022. His annual base salary is £260,000, plus an annual housing and travel budget of £18,000.
- Dr. van Dijk is eligible for an annual cash incentive bonus initially targeted at 35% of base salary, with a maximum payout of 200% of target.
- Both executives are eligible to participate in the company’s employee benefit plans, subject to plan terms.
Severance, Change-in-Control and Equity Provisions
- If Dr. Buell is terminated without cause or resigns following a material reduction in base salary, she may receive 12 months of base salary, the greater of her target bonus or prior-year bonus, 12 months of COBRA medical and dental premiums, and up to $15,000 for outplacement services plus related tax reimbursement.
- Upon a change in control, 50% of Dr. Buell’s outstanding unvested stock options or restricted stock will vest.
- If Dr. Buell is terminated without cause or resigns for good reason or following a compensation reduction within 18 months after a change in control, she may receive 18 months of base salary, 150% of the greater of her target bonus or prior-year bonus, 18 months of COBRA premiums, and up to $15,000 for outplacement services plus related tax reimbursement.
- In that post-change-in-control termination scenario, all of Dr. Buell’s unvested options and restricted stock will immediately vest and become exercisable.
Financial Metrics and Outlook
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating guidance, or other financial performance metrics. It also does not provide a business outlook or forecast.
Investor Verification Points
- Review the executive employment agreements when filed as exhibits to MiNK’s 2021 Form 10-K.
- Assess the potential cash, benefit, tax reimbursement, and equity-acceleration costs associated with termination or a change in control involving Dr. Buell.
- Confirm the effective dates and retroactive compensation treatment for the two executives.
- Monitor the impact of Dr. van Dijk’s change in title from Chief Technology Officer to Chief Scientific Officer.